Overview
LSCIBP
63
Components
$4.3B
Median Mkt Cap
Equal
Weighting
Semi-Annual
Reconstitution
What Is LSCIBP?
The LifeSci Biotechnology Products Index tracks U.S.-listed pure biotechnology companies that have at least one FDA-approved drug therapy generating commercial revenue. With 63 components at equal weight, LSCIBP provides diversified exposure to the proven, revenue-generating segment of the biotech sector.
When to Use LSCIBP
LSCIBP is designed for investors seeking exposure to commercial-stage biotechnology — companies with validated products, recurring revenue, and reimbursement visibility. It serves as a complement to broad healthcare allocations or as a targeted biotech sleeve.
Representative Holdings
| Ticker | Company | Category |
|---|---|---|
| Large Cap | ||
| AMGN | Amgen Inc. | Large Cap |
| GILD | Gilead Sciences | Large Cap |
| VRTX | Vertex Pharmaceuticals | Large Cap |
| Mid Cap | ||
| FOLD | Amicus Therapeutics | Mid Cap |
| ADMA | ADMA Biologics | Mid Cap |
| MIRM | Mirum Pharmaceuticals | Mid Cap |
| Small Cap | ||
| KURA | Kura Oncology | Small Cap |
| ESPR | Esperion Therapeutics | Small Cap |
| GERN | Geron Corporation | Small Cap |
Representative holdings shown. Full constituent list available upon request.